Abstract

Biotechnology Law ReportVol. 41, No. 6 Case in PointCareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 1371Edited for Biotechnology Law Report by Christopher M. HolmanEdited for Biotechnology Law Report by Christopher M. HolmanChristopher M. Holman is a Professor of Law at the University of Missouri–Kansas City School of Law; a Senior Scholar at the Center for the Protection of Intellectual Property at the Antonin Scalia Law School, George Mason University; and the Executive Editor of Biotechnology Law Report.*The synopsis is original content and the decision itself has been condensed for ease of readability.Search for more papers by this authorPublished Online:15 Dec 2022https://doi.org/10.1089/blr.2022.29289.cipAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 41Issue 6Dec 2022 InformationCopyright 2022, Mary Ann Liebert, Inc, publishersTo cite this article:Edited for Biotechnology Law Report by Christopher M. Holman.CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 1371.Biotechnology Law Report.Dec 2022.298-304.http://doi.org/10.1089/blr.2022.29289.cipPublished in Volume: 41 Issue 6: December 15, 2022Online Ahead of Print:November 30, 2022PDF download

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call